An April 10 report
in the Minneapolis Star Tribune said Medtronic PLC did not properly report adverse events during a 2006-2008 chart reviewof its Infuse biologic-based spinal bone-growth device. But Medtronic rebutted...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?